The recent selloff has brought Albemarle to levels that imply its new lithium platform, if anything, is as bad as the bromine platform a few years ago, Jefferies analyst Laurence Alexander tells investors in a research note titled "Trading As If Li Has No Tomorrow, Or At Least Worse Than Br Was." Triggers for a share rally range from stabilization in lithium benchmarks to confirmation customer requirements help longer term contracts remain resilient even when auto manufacturers are curtailing activity, adds the analyst. He finds Albemarle's relative multiple as historically attractive and keeps a Buy rating on the shares with a $150 price target.